Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06464107 · ClinicalTrials.gov registry record · NA
Endometrial Cell Collection With the PadKit
A NA study of Neoplasms, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06464107: Recruiting NA study of Neoplasms, sponsored by Hackensack Meridian Health.
NCT06464107 is a NA study of Neoplasms that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 80 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06464107, a NA study of Neoplasms, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.
Primary Outcome
Direct observation of the absence or presence of endometrial cells on the pad by the pathologist
Conditions Studied
Interventions
- DEVICE PadKit™ from Preprogen
Study Locations (2)
New Jersey
- Jersey Shore University Medical Center - Neptune City
- Riverview Medical Center - Red Bank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2026-05-30 |
| Phase | NA |
What NCT06464107 shows while recruiting
NCT06464107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PadKit™ from Preprogen is the first listed.
NCT06464107 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06464107 about?
NCT06464107 is a clinical study titled "Endometrial Cell Collection With the PadKit". All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial ce...
What is the current status of trial NCT06464107?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-05-31. Estimated completion is 2026-05-30.
What conditions does trial NCT06464107 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06464107?
The interventions under investigation include: PadKit™ from Preprogen (DEVICE).
Who is sponsoring clinical trial NCT06464107?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06464107 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06464107's enrollment target sits among peer trials
80 81st of 158 higher than 77 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
RECRUITING · NA
-
Screening Strategies Among High-risk Populations for Anal Cancer
RECRUITING · NA
-
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI